Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY22 results · Jan–Mar 2022
Natco Pharma reported revenue from operations of ₹596.80 crore (up 80.1% from Q4 FY21) and net loss of ₹50.50 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 596.80 | 331.30 | +80.1% | 560.50 | +6.5% |
| Other income | 13.80 | 28.40 | −51.4% | 30.20 | −54.3% |
| Total income | 610.60 | 359.70 | +69.8% | 590.70 | +3.4% |
| Profit before tax | (49.60) | 70.70 | Turned loss | 91.00 | Turned loss |
| Net profit for the period | (50.50) | 53.00 | Turned loss | 80.40 | Turned loss |
| EPS, basic (₹) | (2.77) | 2.91 | Turned loss | 4.41 | Turned loss |
| Net margin (%) | -8.5 | 16.0 | 14.3 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 514.10 | 311.50 | +65.0% | 529.50 | −2.9% |
| Other income | 10.40 | 29.10 | −64.3% | 31.60 | −67.1% |
| Total income | 524.50 | 340.60 | +54.0% | 561.10 | −6.5% |
| Profit before tax | (67.10) | 73.40 | Turned loss | 79.70 | Turned loss |
| Net profit for the period | (61.30) | 57.20 | Turned loss | 71.60 | Turned loss |
| EPS, basic (₹) | (3.36) | 3.14 | Turned loss | 3.93 | Turned loss |
| Net margin (%) | -11.9 | 18.4 | 13.5 |
Consolidated
- Filed with BSE
- 31 May 2022, 16:14 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 May 2022, 16:14 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE